IE
MSLE

Israel Englander’s Satellos Bioscience MSLE Stock Holding History

Israel Englander’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
152,768
-145,665
-49% -$1M ﹤0.01% 4205
2026
Q1 		$1.68M Buy
+298,433
New +$2.93M ﹤0.01% 4025

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Israel Englander's MSLE Position: Q2 2026 in Review

Israel Englander reduced its Satellos Bioscience (MSLE) stake by 49% in Q2 2026, selling an estimated $1M and leaving 152,768 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4205.

Israel Englander first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.68M in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Israel Englander held 152,768 shares of Satellos Bioscience worth $1.19M as of Q2 2026.
  • Israel Englander sold 145,665 Satellos Bioscience shares in Q2 2026, an estimated $1M.
  • Satellos Bioscience made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4205 holding.
  • Israel Englander first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Israel Englander's Satellos Bioscience position peaked at $1.68M in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.